| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
33,902 |
31,339 |
$2.06M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,611 |
13,440 |
$1.25M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,570 |
6,413 |
$521K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,601 |
5,311 |
$419K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,299 |
2,261 |
$180K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,501 |
3,341 |
$118K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,373 |
6,910 |
$96K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,437 |
1,354 |
$90K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,909 |
2,760 |
$85K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,653 |
2,996 |
$83K |
| 90670 |
|
3,189 |
3,112 |
$68K |
| 90686 |
|
5,570 |
5,436 |
$64K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
649 |
643 |
$56K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,770 |
14,357 |
$53K |
| 92551 |
|
4,627 |
4,542 |
$46K |
| 90677 |
|
586 |
560 |
$32K |
| 90723 |
|
2,172 |
2,106 |
$31K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
209 |
205 |
$26K |
| 90647 |
|
2,201 |
2,137 |
$26K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,087 |
1,026 |
$22K |
| 99188 |
|
837 |
819 |
$18K |
| 90461 |
|
7,894 |
7,698 |
$17K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,895 |
1,859 |
$17K |
| 96127 |
|
2,189 |
2,089 |
$11K |
| 90681 |
|
620 |
602 |
$10K |
| 90716 |
|
379 |
375 |
$8K |
| 90707 |
|
460 |
453 |
$7K |
| 87807 |
|
561 |
523 |
$7K |
| 90633 |
|
493 |
488 |
$6K |
| 99173 |
|
2,128 |
2,090 |
$5K |
| 99072 |
|
1,376 |
1,288 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
106 |
103 |
$5K |
| 90651 |
|
135 |
131 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
121 |
117 |
$4K |
| 90734 |
|
96 |
94 |
$3K |
| 90656 |
|
223 |
220 |
$3K |
| 0071A |
|
53 |
51 |
$2K |
| 99177 |
|
446 |
437 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
758 |
747 |
$1K |
| 0002A |
|
25 |
24 |
$960.00 |
| 0072A |
|
28 |
26 |
$920.00 |
| 90696 |
|
44 |
43 |
$571.85 |
| 0001A |
|
15 |
14 |
$560.00 |
| 85018 |
|
166 |
158 |
$384.27 |
| 90715 |
|
28 |
28 |
$366.48 |
| 83655 |
|
30 |
25 |
$255.56 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
12 |
12 |
$217.68 |
| 90672 |
|
16 |
16 |
$165.00 |
| 81002 |
|
49 |
48 |
$138.85 |
| 91300 |
|
137 |
109 |
$1.01 |
| 91307 |
|
97 |
92 |
$0.72 |